Download presentation
Presentation is loading. Please wait.
Published byFerenc Juhász Modified over 5 years ago
1
Elucidation of asthma phenotypes in atopic teenagers through parallel immunophenotypic and clinical profiling Elysia M. Hollams, PhD, Marie Deverell, PhD, Michael Serralha, BSc(Hons), Devinda Suriyaarachchi, BSc(Hons), Faith Parsons, BSc, Guicheng Zhang, PhD, Nicholas de Klerk, MSc, PhD, Barbara J. Holt, BSc, Claire Ladyman, BSc, Agata Sadowska, BSc(Hons), Julie Rowe, PhD, Richard Loh, FRACP, Peter D. Sly, FRACP, DSc, Patrick G. Holt, DSc Journal of Allergy and Clinical Immunology Volume 124, Issue 3, Pages e16 (September 2009) DOI: /j.jaci Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Fig 1 Wheezing and related phenotypes in the study cohort: spectrum of current asthma, rhinoconjunctivitis, and BHR in the unselected population stratified by atopy. Journal of Allergy and Clinical Immunology , e16DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Fig 2 Degree of sensitization as a risk determinant for asthma and BHR among atopic teenagers. HDM-sensitized subjects (HDM IgE level ≥0.35 kU/L) or subjects with any allergy (any specific IgE level ≥0.35, total IgE level ≥300 kU/L, or both) were analyzed separately. HDM-sensitized subjects (n = 540) were separated into quartiles based on HDM-IgE levels, and the any allergy group (n = 827) were quantified by total IgE level; average probability of asthma, BHR, or both was calculated for each quartile by using univariate logistic regression (P values shown) and normalized against probability for quartile 1. A, Asthma (with or without BHR) versus BHR (with or without asthma). B, Asthma with BHR versus asthma without BHR. Journal of Allergy and Clinical Immunology , e16DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions
4
Fig 3 Immunophenotypic profiling of the study cohort. A, Biomarker expression in the whole population (n = 1380) stratified by HDM sensitization (nonsensitized, n = 840; sensitized, n = 540). Means and SEMs are shown. ∗P < .05, ∗∗ P < .01, and ∗∗∗P < .0005, Mann-Whitney U test. B, Biomarker expression in HDM-sensitized atopic subjects stratified by current asthma status. Means, 95% CIs, and P values (Mann-Whitney U test) are shown. Journal of Allergy and Clinical Immunology , e16DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions
5
Fig 4 Asthma risk and quantitative expression of biomarkers. Subjects in the nonatopic and HDM-sensitized groups were separated into quartiles based on eosinophil (Eos) and neutrophil (PMN) numbers in blood (A) or IL-10 and IFN-γ PHA response capacity (B). Average probability of asthma was calculated for each quartile by using individual univariate logistic regression models (P are values shown). Probabilities for IFN-γ responses were graphed offset by −1.5%. Journal of Allergy and Clinical Immunology , e16DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.